Start here if you're new
what it is
Axis sells specialty insurance and reinsurance, which is plain English for pricing other people’s hard-to-insure risks.
how it gets paid
Last year Axis Capital made $6.6B in revenue.
why it's growing
Revenue grew 10.2% last year. 2024 EPS was $11.18 versus $5.65 in 2023.
what just happened
AXIS posted $3.25 EPS in its last quarter, missing the $3.39 estimate by 4.13%, even as the annual earnings trend stayed strong.
At a glance
A balance sheet — strong enough to weather a downturn
10/100 earnings predictability — expect surprises
8.3x trailing p/e — the market's not buying it — or you found a deal
1.6% dividend yield — cash in your pocket every quarter
14.6% return on capital — nothing to write home about
xvary composite: 68/100 — average
What they do
Axis sells specialty insurance and reinsurance, which is plain English for pricing other people’s hard-to-insure risks.
AXIS wins by living in ugly corners of insurance where pricing matters more than brand. Insurance and reinsurance made up 74% and 26% of 2024 net premiums earned, so you are not relying on one line of business. Return on capital was 14.6%, which means every $1 kept in the business produced about $0.15 in profit.
How they make money
$6.6B
annual revenue · their business grew +10.2% last year
total revenue
$6.6B
+10.2%
The products that matter
underwrites specialty commercial risks
Insurance
$4.9B · 74% of revenue
this is the core $4.9B franchise and roughly 74% of the revenue base. if underwriting execution is strong, you feel it here first.
74% of revenue
assumes insurer risk
Reinsurance
$1.7B · 26% of revenue
this $1.7B segment is smaller, but it gives axis another way to earn premium when pricing is attractive. it also means catastrophe exposure is never far from the story.
26% of revenue
returns excess capital
Share repurchases
$300M authorization
the new $300M buyback will not rescue a bad underwriting year. it does matter because buying in stock at 8.3x earnings is one of the cleaner uses of capital if results hold up.
$300M buyback
Key numbers
$130
18-month target
The published 18-month target is $130 versus $109.10 now, so the upside case is real, but it is not screamingly cheap.
8.3x
trailing p/e
P/E → stock price divided by yearly profit → so what: you are paying $8.30 for each $1 of earnings, which is cheap for a company expected to grow EPS 14.5%.
14.6%
return on capital
Return on capital → profit earned on money kept in the business → so what: AXIS is not just cheap, it is productive.
$1.3B
long-term debt
Debt is 14% of capital, which keeps the balance sheet from becoming the story when insurance losses spike.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 90 / 100
- long-term debt $1.3B (14% of capital)
- return on equity 12% — $0.12 profit for every $1 investors have put in
A — among the top-rated companies for balance sheet quality.
Total return vs. market
You invested $10,000 in AXS 3 years ago → it's now worth $21,710.
The index would have given you $13,920.
source: institutional data · total return
What just happened
missed estimates
AXIS posted $3.25 EPS in its last quarter, missing the $3.39 estimate by 4.13%, even as the annual earnings trend stayed strong.
2024 EPS was $11.18 versus $5.65 in 2023. The business also delivered roughly 6% vs. prior year net premiums earned growth in the third quarter, with insurance offsetting a modest reinsurance decline.
$4.8B
revenue
$3.25
eps
n/a
n/a
the number that mattered
The key number was the 4.13% EPS miss, because cheap insurers get rerated on trust, not just on one quarter of profit.
-
shares of axis capital holdings have advanced nicely in price in recent months.
-
the company reported favorable comparisons for the third quarter.
-
net premiums earned increased roughly 6% vs. prior year.
-
healthy growth from the insurance segment was partly offset by a modest decline at the reinsurance business.
-
underwriting income of $541 million marked an increase of 22% on a year-to-year basis.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
axis capital writes the kind of risks that look profitable until losses arrive all at once. the cheap multiple is real. the reasons for it are real too.
med
catastrophe losses can erase a lot of cheapness fast
axis writes property catastrophe exposure. one ugly event season can do more to valuation than a year of disciplined underwriting can undo.
this is why a stock at 8.3x earnings still carries a 10/100 predictability score.
med
reserve mistakes stay hidden until they do not
specialty and professional lines carry long-tail claims. if reserves were set too optimistically, future earnings have to absorb the correction.
with quarterly revenue at $1.7B, you have scale. you do not have protection from ugly reserve development.
med
management alignment is thinner than you would prefer
officers and directors own less than 1% of the stock. that does not mean careless decisions. it does mean your capital and management's capital are not tightly tied together.
when underwriting gets harder, investors usually prefer executives with more of their own money in the same trade.
med
institutional flow has been mildly negative near the top of the range
there were 204 buyers versus 240 sellers in 3q2025. that is not a collapse in sponsorship, but it is not accumulation either.
when a stock is sitting near the top of a $54–$110 range, soft demand matters more than it sounds.
you are being paid 8.3x earnings because this business can deliver very good years and very messy ones. the A balance sheet helps. it does not repeal insurance math.
source: institutional data · regulatory filings · risk analysis
Pay attention to
valuation
whether 8.3x earnings stays this low
if axis keeps producing around a 15% return on equity, you do not need much multiple help for the stock to work.
risk
catastrophe and reserve volatility
the 10/100 predictability score is not cosmetic. one ugly loss period can rewrite the whole quarter.
trend
institutional sponsorship is soft, not gone
204 buyers versus 240 sellers says big money is cautious. if that turns, sentiment gets easier from here.
earnings
whether the $3.74 quarter was repeatable
EPS rose 83% compared to the prior year on $1.7B of revenue. the next report tells you whether that was durable underwriting strength or favorable loss timing.
Analyst rankings
short-term outlook
average
outlook rank 3 — in human-speak, analysts think the stock is likely to behave roughly like the market from here.
risk profile
above average
risk rank 2 — the balance sheet makes this safer than roughly 80% of stocks even if the business itself stays volatile.
chart momentum
below average
momentum rank 4 — fundamentals look better than the chart right now.
earnings predictability
10 / 100
earnings can swing hard. for insurers, that usually means claims and reserve development are doing the talking.
source: institutional data
Institutional activity
204 buyers vs. 240 sellers in 3q2025. total institutional holdings: 74.4M shares.
source: institutional data
Price targets
3-5 year target range
$91
$168
$109
current price
$130
target midpoint · +19% from current · 3-5yr high: $185 (+70% · 15% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive